Functional characterization of ergothioneine transport by rat organic cation/carnitine transporter OCTN1 (slc22a4)

Department of Membrane Transport and Pharmacokinetics, Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
Biological & Pharmaceutical Bulletin (Impact Factor: 1.78). 09/2008; 31(8):1580-4. DOI: 10.1248/bpb.31.1580
Source: PubMed

ABSTRACT It has been reported that organic cation/carnitine transporter 1 (OCTN1) is associated with rheumatoid arthritis and Crohn's disease. Additionally, we reported that OCTN1 is expressed in hematopoietic cells, and is associated with proliferation and differentiation of erythroid cells. However, physiological role of OCTN1 is still unclear. Ergothioneine, an anti-oxidant, was recently reported to be a good substrate of human OCTN1. However, the transport characteristics of ergothioneine in rat remains to be clarified. The present study, is to further investigate the role of rat Octn1 on transport of ergothioneine in rat Octn1 transfected cells and natively expressing cell line PC12 derived from rat adrenal pheochromocytoma. [(3)H]Ergothioneine uptake by rat Octn1 stably transfected HEK293 cells was saturable, sodium dependent with 1 : 1 stoichiometry of ergothioneine, and pH dependent. Since ergothioneine was reported to presumably play a protective role against oxidative stress-induced apoptosis in PC12 cells, its transport in this cell line was investigated. The expression of rat Octn1 and a saturable and Na(+)-dependent transport of ergothioneine were observed in PC12 cells, suggesting that ergothioneine transport in this cell line may be mediated by rat Octn1. These findings suggested that rat Octn1 may act as a survival factor by taking up ergothioneine to suppress oxidative stress in this cell line. In conclusion, functional characteristics of ergothioneine transport by rat Octn1 is similar to that of human OCTN1 and it is suggested that rat Octn1 is important by transporting anti-oxidant ergothioneine in PC12 cells, though its role in vivo is to be investigated.


Available from: Toshimichi Nakamura, Jan 28, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ergothioneine is a thiourea derivative of histidine found in food, especially mushrooms. Experiments in cell-free systems and chemical assays identified this compound as a powerful antioxidant. Experiments were designed to test the ability of endothelial cells to take up ergothioneine and hence benefit from protection against oxidative stress. RT-PCR and Western blotting demonstrated transcription and translation of an ergothioneine transporter in human brain microvascular endothelial cells (HBMECs). Uptake of [3H]ergothioneine occurred by the organic cation transporter novel type-1 (OCTN-1), was sodium-dependent and was reduced when expression of OCTN-1 was silenced by siRNA. The effect of ergothioneine on the production of reactive oxygen species (ROS) in HBMECs was measured using dichlorodihydrofluorescin and lucigenin, and the effect on cell viability was studied using the 3-(4,5-Dimethylthgiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. ROS production and cell death induced by pyrogallol, xanthine oxidase plus xanthine and high glucose were suppressed by ergothioneine. The antioxidant and cytoprotective effects of ergothionine were abolished when OCTN-1 was silenced using siRNA. The expression of NADPH oxidase 1 was decreased, and those of glutathione reductase, catalase and superoxide dismutase enhanced by the compound. Ergothioneine attenuated the reduction in relaxation of isolated rat basilar arteries to the endothelium-dependent vasodilator acetylcholine caused by pyrogallol, xanthine oxidase plus xanthine or incubation in high glucose. Chronic treatment with the compound improved the response to acetylcholine in arteries of rats with streptozotocin-induced diabetes. In summary, ergothioneine is taken up by endothelial cells via OCTN-1, where the compound then protects against oxidative stress, curtailing endothelial dysfunction.
    Journal of Pharmacology and Experimental Therapeutics 07/2014; 350(3). DOI:10.1124/jpet.114.214049 · 3.86 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The carnitine/organic cation transporter (OCTN) family consists of three transporter isoforms, i.e. OCTN1 (SLC22A4) and OCTN2 (SLC22A5) in humans and animals and Octn3 (Slc22a21) in mice. These transporters are physiologically essential to maintain appropriate systemic and tissue concentrations of carnitine by regulating its membrane transport during intestinal absorption, tissue distribution and renal reabsorption. Among them, OCTN2 is a sodium-dependent, high-affinity transporter of carnitine, and a functional defect of OCTN2 due to genetic mutation causes primary systemic carnitine deficiency (SCD). Since carnitine is essential for beta-oxidation of long-chain fatty acids to produce ATP, OCTN2 gene mutation causes a range of symptoms, including cardiomyopathy, skeletal muscle weakness, fatty liver and male infertility. These functional consequences of Octn2 gene mutation can be seen clearly in an animal model, jvs mouse, which exhibits the SCD phenotype. In addition, although the mechanism is not clear, single nucleotide polymorphisms of OCTN1 and OCTN2 genes are associated with increased incidences of rheumatoid arthritis, Crohn's disease and asthma. OCTN1 and OCTN2 accept cationic drugs as substrates and contribute to intestinal and pulmonary absorption, tissue distribution (including to tumour cells), and renal excretion of these drugs. Modulation of the transport activity of OCTN2 by externally administered drugs may cause drug-induced secondary carnitine deficiency. Octn3 transports carnitine specifically, particularly in male reproductive tissues. Thus, the OCTNs are physiologically, pathologically and pharmacologically important. Detailed characterization of these transporters will greatly improve our understanding of the pathology associated with common diseases caused by functional deficiency of OCTNs. Copyright © 2012 John Wiley & Sons, Ltd.
    Biopharmaceutics & Drug Disposition 01/2013; 34(1). DOI:10.1002/bdd.1816 · 2.18 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Carnitine homeostasis has a pivotal role in the life of mammals. It is realized by the carnitine system, which consists of networks of enzymes and membrane transporters and plays an essential role in functions such as the regulation of the CoA/acyl-CoA ratio, the supply of substrates for the ß-oxidation to mitochondria and peroxisomes and of acyl units for VLDL assembly to the ER, the efflux of acetyl groups from mitochondria during glucose metabolism and the detoxifi-cation of the organism. The network of the transporters plays a crucial role in maintaining homeostasis since it allows the absorption, excretion and re-absorption of carnitine and carnitine derivatives as well as the flux of these metabolites through different tissues and within sub-cellular compartments. Several transport systems which were thought to be in-volved in the network have been identified and characterized to a certain extent. These are the plasma membrane trans-porters OCTN1, 2 and 3, the mitochondrial CACT and the carnitine transport system of endoplasmic reticulum (ERCT). These transporters have been functionally characterized by studies in eukaryotic cell systems and/or in reconstituted liposomes. Interestingly, it was found that some commonly used drugs interact with different carnitine transporters, caus-ing alterations of the transport function by displacing the substrate from the binding site or by irreversibly inactivating the transporters. These interactions will cause derangements of the carnitine homeostasis. The current knowledge of the char-acterization of the carnitine transporter network and the interaction with drugs are reviewed with emphasis to the most re-cent data obtained using the proteoliposome reconstituted systems.
    05/2010; 4(2). DOI:10.2174/187231310791170748